ERBB2 (HER2) protein expression in uterine sarcomas

被引：0

作者：

Zafrakas, M. ^{[1
]}

Zepiridis, L. ^{[1
]}

Theodoridis, T. D. ^{[1
]}

Venizelos, I. D. ^{[2
]}

Papanicolaou, A. ^{[1
]}

Agorastos, T. ^{[1
]}

Bontis, J. N. ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 1, Papageorgiou Gen Hosp, Thessaloniki 56403, Greece

[2] Hippokrateio Gen Hosp, Dept Pathol, Thessaloniki, Greece

来源：

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2009年 / 30卷 / 03期

关键词：

Uterine sarcoma; ERBB2; HER2; Targeted therapy; Trastuzumab; Herceptin (R); Lapatinib; Tykerb (R); METASTATIC BREAST-CANCER; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; OF-THE-LITERATURE; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; TRASTUZUMAB; CARCINOSARCOMA; HER-2/NEU; THERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas. Methods: The expression of ERBB2 has been analyzed immunohistochemical in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11). Results: Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings. Conclusion: Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.

引用

页码：292 / 294

页数：3

共 50 条

[41] HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Prat, Aleix
Pascual, Tomas
De Angelis, Carmine
Gutierrez, Carolina
Llombart-Cussac, Antonio
Wang, Tao
Cortes, Javier
Rexer, Brent
Pare, Laia
Forero, Andres
Wolff, Antonio C.
Morales, Serafin
Adamo, Barbara
Braso-Maristany, Fara
Vidal, Maria
Veeraraghavan, Jamunarani
Krop, Ian
Galvan, Patricia
Pavlick, Anne C.
Bermejo, Begona
Izquierdo, Miguel
Rodrik-Outmezguine, Vanessa
Reis-Filho, Jorge S.
Hilsenbeck, Susan G.
Oliveira, Mafalda
Vittoria Dieci, Maria
Griguolo, Gaia
Fasani, Roberta
Nuciforo, Paolo
Parker, Joel S.
Conte, PierFranco
Schiff, Rachel
Guarneri, Valentina
Osborne, C. Kent
Rimawi, Mothaffar F.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (01): : 46 - 54
[42] ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
Mikulicic, Snjezana
Shamun, Merha
Massenberg, Annika
Franke, Anna-Lena
Freitag, Kirsten
Doering, Tatjana
Strunk, Johannes
Tenzer, Stefan
Lang, Thorsten
Florin, Luise
FRONTIERS IN IMMUNOLOGY, 2024, 15
[43] Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Yoon, Harry H.
Shi, Qian
Sukov, William R.
Wiktor, Anne E.
Khan, Maliha
Sattler, Christopher A.
Grothey, Axel
Wu, Tsung-Teh
Diasio, Robert B.
Jenkins, Robert B.
Sinicrope, Frank A.
CLINICAL CANCER RESEARCH, 2012, 18 (02) : 546 - 554
[44] miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression
Ferracin, Manuela
Bassi, Cristian
Pedriali, Massimo
Pagotto, Sara
D'Abundo, Lucilla
Zagatti, Barbara
Corra, Fabio
Musa, Gentian
Callegari, Elisa
Lupini, Laura
Volpato, Stefano
Querzoli, Patrizia
Negrini, Massimo
MOLECULAR CANCER, 2013, 12
[45] Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
Hein, Alexander
Hartkopf, Andreas D.
Emons, Julius
Lux, Michael P.
Volz, Bernhard
Taran, Florin-Andrei
Overkamp, Friedrich
Hadji, Peyman
Tesch, Hans
Haeberle, Lothar
Ettl, Johannes
Lueftner, Diana
Wurmthaler, Lena A.
Wallwiener, Markus
Mueller, Volkmar
Beckmann, Matthias W.
Belleville, Erik
Wimberger, Pauline
Hielscher, Carsten
Kurbacher, Christian M.
Wuerstlein, Rachel
Thomssen, Christoph
Untch, Michael
Fasching, Peter A.
Janni, Wolfgang
Fehm, Tanja N.
Wallwiener, Diethelm
Brucker, Sara Y.
Schneeweiss, Andreas
Kolberg, Hans-Christian
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 1 - 12
[46] Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
Schillaci, Roxana
Guzman, Pablo
Cayrol, Florencia
Beguelin, Wendy
Diaz Flaque, Maria C.
Proietti, Cecilia J.
Pineda, Viviana
Palazzi, Jorge
Frahm, Isabel
Charreau, Eduardo H.
Maronna, Esteban
Roa, Juan C.
Elizalde, Patricia V.
BMC CANCER, 2012, 12
[47] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
Fumoleau, Pierre
EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
[48] The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer
Lippa, Blaise
Kauffman, Goss S.
Arcari, Joel
Kwan, Tricia
Chen, Jinshan
Hungerford, William
Bhattacharya, Samit
Zhao, Xumiao
Williams, Courtney
Xiao, Jun
Pustilnik, Leslie
Su, Chunyan
Moyer, James D.
Ma, Ling
Campbell, Mary
Steyn, Stefanus
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (11) : 3081 - 3086
[49] Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations
Manrai, Padmini A.
Mchenry, Austin
Sun, Tong
Santin, Alessandro D.
Ratner, Elena
Lin, Douglas I.
Elvin, Julia A.
Hui, Pei
Buza, Natalia
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2025, 44 (02) : 144 - 154
[50] HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides
Wei, Qichun
Xu, Jing
Shen, Li
Fu, Xianhua
Zhang, Bicheng
Zhou, Xiaofeng
Carlsson, Jorgen
TUMOR BIOLOGY, 2014, 35 (07) : 6319 - 6326

← 1 2 3 4 5 →